Forbius Chief Scientific Officer, Dr. Maureen O'Connor-McCourt, to Present at PEGS Boston's 9th Annual Clinical Progress of Antibody-Drug Conjugates

- AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor, on-target toxicity due to novel mechanism of action
- Phase 2 trials ongoing in EGFR-overexpressing (IHC 3+) squamous cell carcinoma of the head and neck (SCCHN) and squamous non-small cell lung cancer (sqNSCLC)
- Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose (RP2D) of 220 mg/m² (~6 mg/kg) q3w, one of the highest amongst ADCs in development and predicted to be in therapeutic range

Austin, TX, and Montreal, QC (Apr. 9, 2019) – Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced today that Dr. Maureen O'Connor-McCourt, Chief Scientific Officer of Forbius, will be presenting an overview of AVID100, a novel, tumor-selective, anti-EGFR antibody-drug conjugate (ADC), at PEGS Boston's 9th Annual Clinical Progress of Antibody-Drug Conjugates.

Details and highlights of Dr. O'Connor-McCourt's presentation:

**Discovery of Next-Generation ADCs: Preclinical and Clinical Development of AVID100, an EGFR-Targeting ADC**

Presentation Friday, April 12th at 11:35 AM ET, Harborview 1 & 2

- AVID100 is highly potent and selectively cytotoxic against EGFR-expressing cancer cells, while sparing normal EGFR-positive keratinocytes
- AVID100 was well-tolerated in a Phase 1 dose-escalation study in patients with advanced solid tumors of epithelial origin (any EGFR status)
  - Only modest skin toxicity observed, in line with preclinical findings
- Phase 2 trial (AVID100-01; NCT03094169) ongoing to evaluate AVID100 efficacy, safety, and tolerability in patients with EGFR-overexpressing (IHC 3+) SCCHN and sqNSCLC

About AVID100 and the AVID100-01 Trial

AVID100 is a highly potent EGFR-targeting antibody-drug conjugate (ADC) that was engineered to achieve enhanced anti-tumor efficacy without a corresponding increase in toxicity against skin and other EGFR-expressing normal tissues. In preclinical studies, AVID100 demonstrated significant anticancer activity, including in EGFR-overexpressing tumor models that are resistant to marketed EGFR
inhibitors. AVID100 is the only anti-EGFR ADC in clinical development that targets both wild-type and mutant forms of EGFR.

In a successfully completed Phase 1 study, AVID100 reported a recommended Phase 2 dose (RP2D) of 220 mg/m\(^2\) (~6mg/kg), which is expected to be in the therapeutically active range based on preclinical efficacy studies. Treatment was generally well-tolerated, with the majority of treatment-related adverse events in the Phase 1 trial at the RP2D being grade 1 or 2 in severity.

AVID100-01 (NCT03094169) is an open label, multicenter study to evaluate the efficacy, safety, and tolerability of AVID100 in patients with confirmed EGFR-overexpressing tumors (more than 50% of cells with EGFR 3+ or more than 75% of cells with EGFR 2+ staining by a validated immunohistochemistry assay).

**About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer**

Forbius is a clinical-stage protein engineering company that designs and develops novel biologics for the treatment of fibrosis and cancer. Our current focus is the development of agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

For more information, please visit [www.forbius.com](http://www.forbius.com).